Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers

被引:0
|
作者
Mahipal, Amit [1 ,2 ]
Bucheit, Leslie [3 ]
Zhang, Nicole [3 ]
Barnett, Reagan M. [3 ]
Storandt, Michael H. [2 ]
Chakrabarti, Sakti [1 ]
机构
[1] Case Western Reserve Univ, Seidman Canc Ctr, Univ Hosp, Cleveland, OH USA
[2] Mayo Clin, Rochester, MN USA
[3] Guardant Hlth Inc, Palo Alto, CA USA
来源
ONCOLOGIST | 2025年 / 30卷 / 03期
关键词
cholangiocarcinoma; pancreatic cancer; gastric cancer; BRAF; cell-free DNA; DABRAFENIB PLUS TRAMETINIB; SINGLE-ARM; OPEN-LABEL; MUTATIONS; MULTICENTER; LANDSCAPE; MELANOMA; PHASE-2; ROAR;
D O I
10.1093/oncolo/oyaf044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Impact of BRAF V600E mutations (BRAF(V600E)), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAF(V600E), understanding the frequency and impact of BRAF alterations across non-CRC GI cancers is essential for clinical decision-making. Methods Patients with PDAC, GEA, HCC, or CCA who had cell-free DNA detected on Guardant360 (Guardant Health) from 2020 to 2023 were queried. Prevalence of characterized BRAF genomic alterations (GA) was calculated; GAs were grouped by class (Class I/II/III). The Chi-squared test assessed differences between cancer types. A subset of patients had outcomes analysis using GuardantINFORM, a real-world clinicogenomic database, to derive real-world overall survival (rwOS). Results Of 32 480 included patients, BRAF GAs were identified in 4.4%; 19% were BRAF(V600E) (0.81% prevalence overall). CCA had the highest rate of BRAF GAs and BRAF(V600E) (P < .01); HCC and GEA had the highest rates of BRAF class II/III alterations. There were no significant differences in rwOS by alteration class or cancer type; numeric differences were observed by alteration class. Few patients were treated with BRAF inhibitors (2.2%). Prevalence of co-occurring alterations was unique by cancer type. Conclusions Frequency of BRAF GAs, including BRAF(V600E), in non-CRC GI cancers detected by liquid biopsy is similar to tissue-based rates and can be reliably used to assess BRAF status. BRAF GAs have mixed prognostic implications on survival for patients with non-CRC GI malignancies that warrant further exploration.
引用
收藏
页数:9
相关论文
共 46 条
  • [41] RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study
    Rachiglio, Anna Maria
    Sacco, Alessandra
    lambiase, MatilDe
    Tufano, Salvatore
    Damato, Angela
    Raimondi, Alessandra
    Frassineti, Luca
    Pazzola, Antonio
    Colombo, Alfredo
    Mosconi, Stefania
    Blasi, Livio
    Sartore-Bianchi, Andrea
    Tamberi, Stefano
    Rossi, Maura
    Romagnani, Elena
    Filiali, Francesca
    Gervasi, Erika
    La Grotteria, Ilenia
    Normanno, Nicola
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials
    Goel, A.
    Xu, C.
    Roy, S.
    Esposito, F. M.
    Helena, O.
    Alonso, V.
    Esteban, A. Yubero
    Carlos, F-M.
    Salvia, M. A. Salud
    Plazas, J. Gallego
    Monwbray, J. R. Rodriguez
    Marta, M. M-R.
    Fernandez, J.
    Manzano, H.
    Aparicio, J.
    Feliu, J.
    Maurel, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S711 - S712
  • [43] Clinical Outcomes of PD-1/PD-L1 Inhibitors Among Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With BRAF, ERBB2/HER2, MET, or RET Alterations: A Systematic Literature Review
    Akers, Katherine G.
    Oskar, Sabine
    Zhao, Bin
    Frederickson, Andrew M.
    Arunachalam, Ashwini
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (04) : 128 - 138
  • [44] Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) plus irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet plus iri: Final results and translational analyses of the CRICKET study by GONO.
    Rossini, Daniele
    Cremolini, Chiara
    Conca, Elena
    Del Re, Marzia
    Busico, Adele
    Pietrantonio, Filippo
    Bergamo, Francesca
    Danesi, Romano
    Casagrande, Mariaelena
    Tamburini, Emiliano
    Dell'Aquila, Emanuela
    Strippoli, Antonia
    Masi, Gianluca
    Tonini, Giuseppe
    Negri, Francesca
    Corsi, Domenico C.
    Ermacora, Paola
    Intini, Rossana
    Falcone, Alfredo
    Santini, Daniele
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program
    Park, Sehhoon
    Olsen, Steve
    Ku, Bo Mi
    Lee, Min-Sang
    Jung, Hyun-Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Choi, Yoon-La
    Ahn, Myung-Ju
    CANCER, 2021, 127 (16) : 3019 - 3028
  • [46] Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)
    Lee, Michael Sangmin
    Parikh, Aparna Raj
    Spigel, David R.
    Dayyani, Farshid
    Spira, Alexander I.
    Atreya, Chloe Evelyn
    Ulahannan, Susanna Varkey
    Strickler, John H.
    Fakih, Marwan
    Grierson, Patrick
    Christenson, Eric
    Outlaw, Darryl Alan
    Khan, Gazala
    Kopetz, Scott
    Bullock, Andrea J.
    Li, Zhengrong
    Chen, Xiaoying
    Patel, Hina
    Hazra, Saswati
    Chiorean, E. Gabriela
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)